KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Non-Current Debt (2023 - 2025)

Biocryst Pharmaceuticals (BCRX) has disclosed Non-Current Debt for 8 consecutive years, with $194.4 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Non-Current Debt fell 38.17% year-over-year to $194.4 million, compared with a TTM value of $194.4 million through Sep 2025, down 38.17%, and an annual FY2024 reading of $314.9 million, up 3.84% over the prior year.
  • Non-Current Debt was $194.4 million for Q3 2025 at Biocryst Pharmaceuticals, down from $242.8 million in the prior quarter.
  • Across five years, Non-Current Debt topped out at $315.4 million in Q1 2025 and bottomed at $194.4 million in Q3 2025.
  • Average Non-Current Debt over 3 years is $284.6 million, with a median of $303.2 million recorded in 2023.
  • The sharpest move saw Non-Current Debt surged 32.67% in 2024, then tumbled 38.17% in 2025.
  • Year by year, Non-Current Debt stood at $303.2 million in 2023, then rose by 3.84% to $314.9 million in 2024, then tumbled by 38.27% to $194.4 million in 2025.
  • Business Quant data shows Non-Current Debt for BCRX at $194.4 million in Q3 2025, $242.8 million in Q2 2025, and $315.4 million in Q1 2025.